|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit. |
| 公司地址
| 525 Collins Street, Rialto South Tower Level 23, Melbourne, VIC, AUS, 3008 |
| 電話號碼
| +61 409840786 |
| 傳真號碼
| +61 425703805 |
| 公司網頁
| https://www.incannex.com.au |
| 員工數量
| 12 |
| Mr. Lekhram Changoer |
Chief Technology Officer |
-- |
28/10/2026 |
| Mr. Joel Latham |
Director, Chief Executive Officer and President |
美元 790.00K |
28/10/2026 |
| Mr. Joseph Swan |
Principal Accounting Officer, Chief Financial Officer and Secretary |
美元 198.26K |
28/10/2026 |
| Dr. Luigi M. Barbato, M.D. |
Chief Medical Officer |
美元 375.00K |
28/10/2026 |
|
|
| Dr. George E. Anastassov, M.D. |
Independent Director |
28/10/2026 |
| Mr. Joel Latham |
Director, Chief Executive Officer and President |
28/10/2026 |
| Mr. Troy Valentine |
Chairman of the Board |
28/10/2026 |
| Mr. Peter Widdows |
Independent Director |
28/10/2026 |
| Mr. Robert Clark |
Independent Director |
28/10/2026 |
|
|
|
|